Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

@article{Nakamura2007Antigp210AA,
  title={Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis},
  author={Minoru Nakamura and Hisayoshi Kondo and Tsuyoshi Mori and Atsumasa Komori and Mutsumi M. Matsuyama and Masahiro Ito and Yasushi Takii and Makiko Koyabu and Terufumi Yokoyama and Kiyoshi Migita and Manabu Daikoku and Seigo Abiru and Hiroshi Yatsuhashi and Eiichi Takezaki and Naohiko Masaki and Kazuhiro Sugi and Koichi Honda and Hiroshi Adachi and Hidehiro Nishi and Yukio Watanabe and Yoko Nakamura and Masaaki Shimada and Tatsuji Komatsu and Akira Saito and Takeo Saoshiro and Hideharu Harada and Takeshi Sodeyama and Shigeki Hayashi and Akihide Masumoto and Takehiro Sando and Tetsuo Yamamoto and Hironori Sakai and Masakazu Kobayashi and Toyokichi Muro and Michiaki Koga and Zakera Shums and Gary L. Norman and Hiromi Ishibashi},
  journal={Hepatology},
  year={2007},
  volume={45}
}
The predictive role of antinuclear antibodies (ANAs) remains elusive in the long‐term outcome of primary biliary cirrhosis (PBC). The progression of PBC was evaluated in association with ANAs using stepwise Cox proportional hazard regression and an unconditional stepwise logistic regression model based on the data of 276 biopsy‐proven, definite PBC patients who have been registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). When death of hepatic… 
Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis
TLDR
Evaluation of ACA and kidney function is necessary to prevent CKD progression in PBC patients, and ACA is an independent risk factor for CKD in P BC.
Predictive role of anti‐gp210 and anticentromere antibodies in long‐term outcome of primary biliary cirrhosis
TLDR
The clinical significance of antinuclear antibodies in primary biliary cirrhosis patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ) is studied and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens are discussed.
Anti‐gp210 and anti‐centromere antibodies for the prediction of PBC patients with an incomplete biochemical response to UDCA and bezafibrate
TLDR
The results suggest that the status of anti-gp210 and anticentromere antibodies may predict not only long-term prognosis but also biochemical response to treatment in PBC patients.
The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
  • Qingling Chen, Rui Zhong, +5 authors Q. Jin
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2021
TLDR
In this cohort of UDCA-treated PBC patients, positivity for anti-gp210 antibody was independently associated with a higher risk of liver-related death or transplantation.
Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis
TLDR
PBC-specific Gp120 antibodies are optimal predictors of PBC prognosis at the time of diagnosis, and some other liver function indicators, such as ALP and IgM, can be used as predictors to complement Gp210 antibodies to establish a stratification tool to predict the prognosis.
Anti‐gp210 antibody mirrors disease severity in primary biliary cirrhosis
TLDR
It is shown that antigp210 is a biomarker of disease severity in PBC, partially concurring with the findings from Japan, and the autoantibody prevalence is much lower—less than half—in Mediterranean populations, in whom it also fails to act as a prognostic marker.
Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients.
TLDR
The presence of ANEA and anti-gp210 identifies a subgroup of PBC patients with advanced disease severity and poor prognosis, and is correlated with clinical data, histology, and survival.
The value of antinuclear antibodies in primary biliary cirrhosis
TLDR
Both anti-gp210 antibody and ACA are related to severe disease course and poor prognosis in primary biliary cirrhosis patients and further examinations should be made to detect underlying SjS.
Genome‐wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis
TLDR
A genome‐wide association analysis of 930 PBC cases indicated significant genetic predisposition to the sp100 autoantibody, but not the gp210 autoantIBody, subphenotype in PBC patients.
Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis
abstract Objectives Antimitochondrial antibodies (AMA) are a sensitive and specific marker for primary biliary cirrhosis (PBC). AMAs are present in 95% of patients with PBC. However, 5% do not have
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
TLDR
Antinuclear antibody markers, and anti-centromere antibodies in particular, are associated with liver failure in PBC, and PBC patients with ANAs may be candidates for treatment with experimental therapies to prolong the interval between diagnosis and liver failure.
Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis
TLDR
Re retrospective analysis of sera from a clinically well‐defined Canadian series of 170 PBC patients included into a 24‐month therapeutic trial of ursodeoxycholic acid (UDCA) implies that UDCA can modulate immunoglobulin (Ig) expression not only quantitatively, but also qualitatively.
Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
TLDR
The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
Characterization and Clinical Impact of Antinuclear Antibodies in Primary Biliary Cirrhosis
TLDR
Positivity for anti-Sp100, anti-gp210, and anti-lamin B receptor, either alone or in combination, may act as a serologic marker of antimitochondrial antibodies negative primary biliary cirrhosis.
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of
Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis
TLDR
PBC specific ANA, in particular of the IgG3 isotype, are associated with a more severe disease course, possibly reflecting the peculiar ability of this isotype to engage mediators of damage.
Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.
TLDR
The presence of anti-p62 complex antibody may be related with the progressive or advanced state of PBC, and the confirmation of Scheuer's stage IV was found to be statistically significant.
High prevalence of antibodies to recombinant CENP‐B in primary biliary cirrhosis: Nuclear immunofluorescence patterns and ELISA reactivities
TLDR
The findings suggest that recombinant CENP‐B ELISA appears to be more sensitive in identifying ACA than IIF, underlying its potential value as a screening test for the diagnosis of PBC complicated with other autoimmune‐like disorders.
Antimitochondrial antibodies in primary biliary cirrhosis.
TLDR
increasing evidence, including the specific association of AMA with PBC, suggests that AMA is not an epiphenomenon of the disease but plays a significant role in the pathogenesis of PBC.
Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis
TLDR
It is suggested that the presence of anti‐gp210 is one of the independent prognostic markers able to predict, at the time of diagnosis, a poor outcome in patients with PBC.
...
1
2
3
4
5
...